NASDAQ:SAGE - SAGE Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $171.03 +7.62 (+4.66 %) (As of 05/22/2019 02:40 AM ET)Previous Close$163.41Today's Range$163.30 - $171.2652-Week Range$79.88 - $177.05Volume432,400 shsAverage Volume588,319 shsMarket Capitalization$8.75 billionP/E RatioN/ADividend YieldN/ABeta2.87 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Receive SAGE News and Ratings via Email Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAGE Previous Symbol CUSIPN/A CIK1597553 Webhttp://www.sagerx.com/ Phone617-299-8380Debt Debt-to-Equity Ratio0.03 Current Ratio20.06 Quick Ratio20.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90.27 million Price / Sales96.91 Cash FlowN/A Price / Cash FlowN/A Book Value$25.80 per share Price / Book6.63Profitability EPS (Most Recent Fiscal Year)($8.08) Net Income$-372,880,000.00 Net MarginsN/A Return on Equity-43.47% Return on Assets-40.57%Miscellaneous Employees637 Outstanding Shares51,148,000Market Cap$8.75 billion Next Earnings Date8/6/2019 (Estimated) OptionableOptionable SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions What is SAGE Therapeutics' stock symbol? SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE." How were SAGE Therapeutics' earnings last quarter? SAGE Therapeutics Inc (NASDAQ:SAGE) posted its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($3.37) EPS for the quarter, missing analysts' consensus estimates of ($3.17) by $0.20. The biopharmaceutical company had revenue of $0.47 million for the quarter. During the same period last year, the business posted ($1.68) earnings per share. View SAGE Therapeutics' Earnings History. When is SAGE Therapeutics' next earnings date? SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for SAGE Therapeutics. What price target have analysts set for SAGE? 14 brokerages have issued 12-month price objectives for SAGE Therapeutics' stock. Their forecasts range from $80.00 to $261.00. On average, they anticipate SAGE Therapeutics' stock price to reach $201.75 in the next twelve months. This suggests a possible upside of 18.0% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics. What is the consensus analysts' recommendation for SAGE Therapeutics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics. Has SAGE Therapeutics been receiving favorable news coverage? Press coverage about SAGE stock has been trending neutral on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SAGE Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of SAGE Therapeutics' key competitors? Some companies that are related to SAGE Therapeutics include Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF) and Bausch Health Companies (BHC). What other stocks do shareholders of SAGE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), Micron Technology (MU), Intercept Pharmaceuticals (ICPT), Twitter (TWTR), Celgene (CELG), AbbVie (ABBV), Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD). Who are SAGE Therapeutics' key executives? SAGE Therapeutics' management team includes the folowing people: Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)Mr. Michael Cloonan, Chief Bus. Officer (Age 48) Who are SAGE Therapeutics' major shareholders? SAGE Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.87%), BlackRock Inc. (5.23%), Jennison Associates LLC (4.61%), Wellington Management Group LLP (4.32%), Janus Henderson Group PLC (3.54%) and OppenheimerFunds Inc. (2.82%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics. Which major investors are selling SAGE Therapeutics stock? SAGE stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Oak Ridge Investments LLC, Carillon Tower Advisers Inc., Rhenman & Partners Asset Management AB, Marshall Wace LLP, Strs Ohio, Victory Capital Management Inc. and Tocqueville Asset Management L.P.. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics. Which major investors are buying SAGE Therapeutics stock? SAGE stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Janus Henderson Group PLC, FMR LLC, TimesSquare Capital Management LLC, Artisan Partners Limited Partnership, Wellington Management Group LLP, Frontier Capital Management Co. LLC and BlackRock Inc.. View Insider Buying and Selling for SAGE Therapeutics. How do I buy shares of SAGE Therapeutics? Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is SAGE Therapeutics' stock price today? One share of SAGE stock can currently be purchased for approximately $171.03. How big of a company is SAGE Therapeutics? SAGE Therapeutics has a market capitalization of $8.75 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe. What is SAGE Therapeutics' official website? The official website for SAGE Therapeutics is http://www.sagerx.com/. How can I contact SAGE Therapeutics? SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected] MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 474 (Vote Outperform)Underperform Votes: 256 (Vote Underperform)Total Votes: 730MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: How Do Mutual Funds Work? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.